

UROTHELKARZINOM

VOLGA: A phase 3 randomized, open-label, multicenter study to determine the efficacy and safety of Durvalumab in combination with Tremelimumab and Enfortumab vedotin or Durvalumab in combination with Enfortumab vedotin for perioperative treatment in patients ineligible for cisplatin undergoing radical cystectomy for muscle invasive bladder cancer (Sponsor: AstraZeneca)

Closed for recruitment 23.10.2024

DURAVELO-2: A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

PROSTATAKARZINOM

ARASTEP: A randomized, double-blind, placebo-controlled Phase 3 study of Darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer (Sponsor: Bayer)

EVO-PAR: A randomised, double-blind, placebo-controlled, phase III study of AZD5305 in combination with physician's choice new hormonal agents in participants with metastatic castration-sensitive prostate cancer with and without HRRm (Sponsor: AstraZeneca)

Voraussichtlicher Start: 4. Quartal 2024

ARASAFE: A randomised, phase 3 trial comparing 3-weekly Docetaxel 75 mg/m² versus 2-weekly Docetaxel 50 mg/m² in combination with darolutamide + ADT in patients with mHSPC (Sponsor: Friedrich-Schiller-Universität Jena, Deutschland)

Closed for recruitment 23.10.2024

Prostate cancer outcomes – compare & reduce variation in DKG-zertifizierten Prostatakrebszentren

NIERENZELLKARZINOM

STELLAR 002: A dose-escalation and expansion study of the safety and efficacy of XL092 in combination with immunology agents in subjects with unresectable advanced or metastatic solid tumors (Sponsor: Exelixis)